At a glance
ClinicalIndex Comparison Record- ✓Age 18 to 70 years
- ✓Free of immunosuppression for at least 3 months
- ✓Capability of understanding the purpose of the study
- ✓Written informed consent
- ✕eGFR <30 mL/min/1.73m²
- ✕Prior kidney transplant
- ✕Secondary membranous nephropathy (defined on basis of clinical criteria)
- ✕Type 1 or Type 2 diabetes mellitus
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy
In Brief
A Phase 4 clinical trial evaluating ACTHar for Membranous Nephropathy. Completed, enrolled 5 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effect of adrenocorticotropic hormone (ACTH, Acthar) on the loss of proteins in the urine (proteinuria) in patients with membranous nephropathy. Acthar is a hormone that stimulates steroid production from small glands above the kidneys. It has direct protective effects on the kidney and is currently approved by the FDA to treat kidney disorders associated with proteins in the urine, but the mechanisms of action are not entirely understood and will be studied in the present trial.
Study Details
Timeline
Interventions
for 6 months